Email this article Prognostic value of immunological components of tumor microenvironment of oncourological tumors
- Authors: Molchanov O.E.1, Maistrenko D.N.1, Granov D.A.1, Shkolnik M.I.1, Lisitsyn I.Y.1, Belov A.D.1, Kneev A.Y.1
-
Affiliations:
- A.M. Granov Russian Research Center of Radiology and Surgical Technologies
- Issue: Vol 13, No 4 (2023)
- Pages: 323-337
- Section: Original articles
- URL: https://journals.rcsi.science/uroved/article/view/251894
- DOI: https://doi.org/10.17816/uroved623621
- ID: 251894
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: In the last decade, the tumor microenvironment has been considered as one of the key factors determining the prognosis and nature of the necessary therapeutic interventions. Currently, there is only one validated and approved predictive model that includes microenvironment components. Several classifications of the tumor microenvironment based on the nature of the predominant cellular subpopulations have been proposed.
AIM: The aim of the study was to assess the prognostic significance of the immunological components of blood and the microenvironment, as well as to create prognostic models for oncourological tumors.
MATERIALS AND METHODS: The study used clinical data from 115 patients with kidney, bladder and prostate cancer. Immunological parameters in the tumor and blood microenvironment were evaluated in all patients. The end point of observation was the median time to progression. The influence of various parameters on long-term treatment outcomes was evaluated using the log rank and the Gehan–Wilcoxon criteria. A model of proportional hazard was used to identify the combined effect of several parameters on lifetime indicators.
RESULTS: The developed prognostic models for all studied groups include spontaneous production of three cytokines: IL-6, IL-8 and IL-10. The prognostic models for renal cell carcinoma and prostate cancer also included immunosuppressive components: MDSC and Treg. The median time to progression in patients with invasive urothelial cancer is influenced by components that contribute to tumor destruction: TNK cells and IFN-γ. In all the studied groups of patients (renal cell carcinoma, muscle-invasive urothelial cancer, prostate cancer), the median time to progression significantly differs in subgroups with different numbers of immunological risk factors for tumor microenvironment.
CONCLUSIONS: The developed prognostic models are based on modern achievements of oncoimmunology and after conducting multicenter validation studies, they can be recommended for clinical use.
Full Text
##article.viewOnOriginalSite##About the authors
Oleg E. Molchanov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Author for correspondence.
Email: molchanovo@mail.ru
ORCID iD: 0000-0003-3882-1720
SPIN-code: 5557-6484
Scopus Author ID: 25637650600
MD, Dr. Sci. (Medicine)
Russian Federation, Saint PetersburgDmitrii N. Maistrenko
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: may64@inbox.ru
ORCID iD: 0000-0001-8174-7461
SPIN-code: 7363-4840
Scopus Author ID: 57193120885
MD, Dr. Sci. (Medicine)
Russian Federation, Saint PetersburgDmitrii A. Granov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: d.granov@gmail.ru
ORCID iD: 0000-0002-8746-8452
SPIN-code: 5256-2744
MD, Dr. Sci. (Medicine), Professor, Academician of the Russian Academy of Sciences
Russian Federation, Saint PetersburgMikhail I. Shkolnik
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: shkolnik_phd@mail.ru
ORCID iD: 0000-0003-0589-7999
SPIN-code: 4743-9236
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint PetersburgIgor Yu. Lisitsyn
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: urologlis@mail.ru
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgAndrei D. Belov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: doktorbeloff@gmail.com
ORCID iD: 0000-0002-9652-4313
SPIN-code: 2637-0704
Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgAleksei Yu. Kneev
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Email: alexmedspb@gmail.com
ORCID iD: 0000-0002-5899-8905
SPIN-code: 8015-1529
Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgReferences
- Yang L, Lin PS. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol. 2017;47:185–195. doi: 10.1016/j.semcancer.2017.08.001
- Buoncervello M, Gabriele L, Toschi E. The Janus face of tumor microenvironment targeted by immunotherapy. Int J Mol Sci. 2019;20(17):4320. doi: 10.3390/ijms20174320
- Jarosz-Biej M, Smolarczyk R, Cihon T, Kulach N. Tumor microenvironment as a “Game Changer” in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212. doi: 10.3390/ijms20133212
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322. doi: 10.1016/j.ccr.2012.02.022
- Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22(1):329–360. doi: 10.1146/annurev.immunol.22.012703.104803
- Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol. 2023;16(1):38. doi: 10.1186/s13045-023-01430-8
- Talukdar S, Bhoopathi P, Emdad L, et al. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84. doi: 10.1016/bs.acr.2018.12.002
- Zeng Z, Fu M, Hu Y, et al. Regulation and signaling pathways in cancer stem cells: implication for targeted therapy for cancer. Mol Cancer. 2023;22(1):172. doi: 10.1186/s12943-023-01877-w
- Locati M, Curtale G, Mantovani A. Diversity, Mechanisms and significance of macrophage plasticity. Annu Rev Pathol. 2020;15: 123–147. doi: 10.1146/annurev-pathmechdis-012418-012718
- Zhao L, Dong Y, Zhang Y, et al. Biophysical heterogeneity of myeloid-derived microenvironement to regulate resistance to cancer immunotherapy. Adv Drug Deliv Rev. 2022;191:114585. doi: 10.1016/j.addr.2022.114585
- Ohue Y, Nishikava H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7): 2080–2089. doi: 10.1111/cas.14069
- Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019;20(1): 7–24. doi: 10.1038/s41577-019-0210-z
- Wu Z, Zheng Y, Han Y, et al. CD3+CD4+CD8-(double-negative) T cells in inflammation, immune disorders and cancer. Front Immunol. 2022;13:816005. doi: 10.3389/fimmu.2022.816005
- Bruchard M, Ghiringhelli F. Deciphering the roles of innate lymphoid cells in cancer. Front Immunol. 2019;10:656. doi: 10.3389/fimmu.2019.00656
- Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671–688. doi: 10.1038/s41577-018-0061-z
- Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689–713. doi: 10.1007/s00018-017-2686-7
- Molchanov O, Maistrenko D, Granov D, et al. Features of the microenvironment of oncourological tumors. Urology reports (St. Petersburg). 2022;12(4):313–331. doi: 10.17816/uroved112576
- Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(1035):2128–2139. doi: 10.1016/S0140-6736(18)30789-X
- Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumors with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi: 10.1038/s41573-018-0007-y
- Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma. World J Urol. 2018;36(12): 1943–1952. doi: 10.1007/s00345-018-2309-4
- Molchanov O, Maistrenko D, Granov D, Lisitsyn I. Prognostic value of tumor growth rate and biomarker dynamics in patients with renal cell carcinoma. Urology Reports (St. Petersburg). 2020;10(4): 281–291. doi: 10.17816/uroved50899
- Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi: 10.1200/jco.2008.21.4809
- Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline. Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026
- Khaydukov S, Baidun L, Zurochka A, Totolyan A. Standardized technology “Study of subpopulation composition of peripheral blood lymphocytes using flow cytofluorimeters-analyzers”. Medical Immunology (Russia). 2012;14(3):255–268. (In Russ.) doi: 10.15789/1563-0625-2012-3-255-268
- Anker J, Miller J, Taylor N, et al. From bench to bedside: how the tumor microenvironement is impacting the future of immunotherapy for renal cell carcinoma. Cells. 2021;10(11):3231. doi: 10.3390/cells10113231
- Amsberg G, Alsdorf W, Karagiannis P, et al. Immunotherapy in advanced prostate cancer — light at the end of the tunnel? Int J Mol Sci. 2022;23(5):2569. doi: 10.3390/ijms23052569
- Crispen P, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69(1):3–14. doi: 10.1007/s00262-019-02443-4
